Denis Patrick, Senior Director & Head, External R&D Innovation, Oncology Research Unit at Pfizer to give a Featured Presentation on “Antibody Drug Conjugation Technology: Past, Present and Future” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
Antibody Drug Conjugation Technology: Past, Present and Future
The promise of Antibody Drug Conjugation (ADC) technology is beginning to come to fruition. Early examples of this technology have paved the way for the current crop of exciting ADC drugs in late clinical development as well as the recently launched Adcetris. These recent successes will generate excitement, investment, and an appetite for the next generation ADCs. This presentation will highlight key findings from past and present programs. The primary objective of this presentation is to outline strategies for advancing state of the art and next generation ADC technologies and ultimately to accelerate these drugs into the clinic where they can benefit patients.
Denis Patrick, Ph.D., joined Pfizer in August of 2010 as Senior Director and Head of External R&D Innovation (ERDI) for the Oncology Research Unit (ORU). The goal of ERDI is to identify external opportunities that are focused on areas that complement Pfizer’s ORU research interests including antibody drug conjugation (ADC) technologies, emerging sciences, oncogenic drivers, biolomics, and precision medicine strategies. Recent external collaborations include Macrogenics’ T-DART technology, Seattle Genetics’ auristatin payloads and linkers for ADCs, and several Scripps Institute collaborations. Prior to Pfizer, Dr. Patrick worked at GlaxoSmithKline for eight years, initially as director of Oncology Biology followed by Director of Oncology Scientific Licensing. Dr. Patrick was instrumental in evaluating and executing collaboration agreements with Japan Tobacco Company for a MEK inhibitor, 1120212, now in phase III studies, Amplimmune’s AMP224 now in phase I, and research agreements with Supergen, Vernalis, Proteologics, and Seattle Genetics. During his time as Director of Oncology Biology, Dr. Patrick lead preclinical research groups delivering numerous clinical candidates, the most advanced of which is GSK’s B-Raf inhibitor, 2118436, now in phase III for metastatic melanoma. Prior to GSK, Dr. Patrick worked at DuPont Pharma for 3 years and Merck Research Labs for 11 years. Denis obtained his Ph.D. in Biochemistry from the University of Pennsylvania.
The Oncology Partnering & Deal Making Conference is a partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant issues in Oncology and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about Oncology business development trends, market, and novel technologies that shape up the industry.
The top companies and experts in the Oncology field will come together to discuss the latest discoveries, technologies and partnership opportunities from their organization. Companies include Array Biopharma, A&G Pharmaceutical, Amgen, Astellas Pharma, Aveo ¬¬¬¬¬¬Pharmaceuticals, Boehringer Ingelheim, Eisai , Eli Lilly, Endocyte, Epizyme, Epic Sciences, Micromet, Novartis, OncoMed, Pfizer , Plexxikon , Pullan Consulting, QIAGEN, SAIC-Frederick, Seattle Genetics, Third Rock Ventures, YM Biosciences, and many more!
The conference is part of the Targets and Strategies in Drug Discovery Summit, which consists of 4 tracks including the 2nd Ubiquitin Research and Drug Discovery , 4th Ocular Diseases & Drug Discovery , and 3rd Cancer Targets and Therapeutics Conference.
For more information, please visit www.gtcbio.com
